JNJ-54767414 clinical trials

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

This study looks at a new drug called daratumumab to see if it can stop a high-risk precancerous blood condition, called smouldering multiple myeloma, from turning into a more serious cancer. It compares the drug to close observation to see which approach works best.